Tangutorine (1) in the racemic form has been assembled from tryptamine and aldehyde 3. The synthetic design was based on uncovering a hidden symmetry in the nontryptamine portion of the norketone 2. A five-step process with an overall yield of 7% was developed in which 2 was transformed into the target molecule via a Vilsmeier–Haack reaction and two reduction steps.
No takes yet. Share an insight, caveat, or question.
Ho et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: